Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3392405 | 1.00 | SLC6A5 (0.48) | SLC6A5MEN1KMT2AEPHX2REN | |
| SCHEMBL18381256 | 0.81 | SLC6A5 (0.57) | SLC6A5EPHX2RENCCR2 | |
| SCHEMBL21852767 | 0.80 | ERAP2 (0.54) | SLC6A5REN | |
| SCHEMBL28808810 | 0.79 | SLC6A5 (0.69) | SLC6A5KMT2AEPHX2 | |
| SCHEMBL19051482 | 0.79 | SLC6A5 (0.53) | SLC6A5EPHX2CCR2 | |
| SCHEMBL18381283 | 0.79 | SLC6A5 (0.51) | SLC6A5EPHX2CCR2 | |
| SCHEMBL18381317 | 0.77 | SLC6A5 (0.51) | SLC6A5EPHX2CCR2 | |
| SCHEMBL29713992 | 0.77 | SLC6A5 (0.77) | SLC6A5EPHX2 | |
| SCHEMBL16070708 | 0.77 | SLC6A5 (0.77) | SLC6A5EPHX2 | |
| SCHEMBL27352063 | 0.76 | SLC6A5 (0.54) | SLC6A5RENHDAC1HDAC6CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737819-B1 | AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE | DSM IP ASSETS BV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | DSM IP ASSETS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | DSM IP ASSETS B.V. (NL) | 2010-04-22 | — | — | US | disclosed |
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | DSM IP ASSETS B.V. (NL) | 2008-09-25 | — | — | US | disclosed |
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | DSM IP ASSETS B.V. (NL) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234344-A1 | Amino Acid and Peptide Conjugates of Arylalkylic Acids for Cosmetic Use | NGLY1, HRH4, C3AR1 | SLC6A5 2345/4885MEN1 993/4885KMT2A 2235/4885 |
| US-20100099727-A1 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use | NGLY1, HRH4, C3AR1 | SLC6A5 2345/4885MEN1 993/4885KMT2A 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.